You're browsing as a guest. Sign in to unlock all features.

PM

Philip Morris International Inc.·Tobacco·United States

Philip Morris International Inc. operates as a tobacco company. The company offers cigarettes and smoke-free products, including heat-not-burn, e-vapor, and oral nicotine products under the IQOS, VEEV...

3 Total3 External0 In-site
PMPhilip Morris International Inc.
2026-04-29
🛒 Consumer DefensivePitch
Externalby Recital · Substack

Recital on Philip Morris International Inc. (PM)

主要经营地

美国

详细生意模式

全球烟草巨头,业务涵盖传统卷烟与无烟产品组合,包括加热不燃烧产品IQOS、电子烟VEEV以及口服尼古丁产品ZYN,国际市场卷烟提价能力强劲,多类别无烟产品形成增长引擎,定价权与品牌组合驱动稳定现金流。

护城河

🟢强:全球品牌矩阵+IQOS技术专利+无烟产品先发优势+国际定价权+分销网络规模壁垒

估值水平

PE 22.9x, EV/EBITDA 15.8x

EV/Market Cap

EV $302.1B / MC $253.6B

网络观点

Q1 EPS $1.96超预期7%,营收$10.1B同比+1.7%,重申FY26指引营收+5-7%、营业利润+7-9%、EPS+7.5-9.5%。ZYN美国出货量-30.8%但IQOS国际市场销售+10.9%、VEEV达10亿支、国际卷烟定价+8.5%。股价财报后+8%反映市场重估多类别韧性而非ZYN依赖度,看涨情绪占主导。

AI观点

PM展现典型多元化烟草巨头韧性,无烟产品组合多元化降低ZYN单点风险,IQOS国际放量与VEEV扩张构成长期增长支柱。22.9倍PE对应7-9%EPS增长属合理估值,67.3%毛利率与稳定FCF $9.56B支撑分红能力。负ROE反映会计处理而非经营恶化。风险在于ZYN美国疲软延续、监管收紧及汇率波动,但定价权+IQOS渗透率提升应足以对冲。整体属于防御性高质量复利标的。

PMPhilip Morris International Inc.
2025-09-29
🛒 Consumer DefensivePitch
Externalby First Eagle Global Fund · YellowBrick

First Eagle Global Fund Portfolio Holding: Philip Morris International Inc.

Philip Morris International (PM) demonstrated strong earnings, though sales were impacted by regulatory issues in Indonesia and Turkey. The company's growth is increasingly reliant on its noncombustible product segment. It is characterized as a cash-flow-generative business that provides robust shareholder returns through dividends and buybacks. The author maintains a constructive view on the company's dependable cash generation capabilities.

PMPhilip Morris International Inc.
2025-05-06
🛒 Consumer DefensiveAnalysis
Externalby Sohini Mondal · Other

Are Wall Street Analysts Predicting Philip Morris Stock Will Climb or Sink?

Philip Morris International (PM) has significantly outperformed the market, with its stock surging 78.1% over the past 52 weeks. The company's transition to a smoke-free future, driven by products like IQOS and ZYN, is a key growth driver, with smoke-free products accounting for 42% of total revenues in Q1 2025. Following strong Q1 results and an increased full-year EPS guidance, Wall Street analysts hold a 'Strong Buy' consensus rating on the stock, indicating a positive outlook on its future performance.